The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience

Pharmacology and Therapeutics

Volumn 148, Issue , 2015, Pages 132-153

  Berman, David ^a   Korman, Alan ^a   Peck, Ronald ^a   Feltquate, David ^a   Lonberg, Nils ^a   Canetta, Renzo ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Combinations; Immuno oncology; Ipilimumab; Nivolumab; Novel evaluation criteria; T cell receptors

Indexed keywords

BMS 936559; CD137 LIGAND; CD27 ANTIGEN; CD70 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; LIRILUMAB; LYMPHOCYTE ACTIVATION GENE 3; NIVOLUMAB; PEPTIDES AND PROTEINS; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; URELUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ABSCESS; ASTHENIA; CANCER IMMUNOTHERAPY; COLITIS; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENDOCRINE DISEASE; ENTEROCOLITIS; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GUILLAIN BARRE SYNDROME; HEMOPHILIA; HEPATITIS; HUMAN; HYPOGONADISM; HYPOPIGMENTATION; HYPOPITUITARISM; HYPOTHYROIDISM; IMMUNOMODULATION; INTESTINE PERFORATION; KIDNEY CANCER; KIDNEY CARCINOMA; LIBIDO DISORDER; LUNG CANCER; LUPUS ERYTHEMATOSUS NEPHRITIS; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; MYASTHENIA GRAVIS; NEPHRITIS; NEUROPATHY; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCREAS CANCER; PERICARDITIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROCTITIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PRURITUS; RASH; REVIEW; SARCOIDOSIS; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; UVEITIS; VITILIGO; ANIMAL; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS;

EID: 84923274682     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.11.017     Document Type: Review

References (253)

1. A. Ackerman, D.F. McDermott, D.P. Lawrence, A. Gunturi, K.T. Flaherty, and A. Giobbie-Hurder Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib J Clin Oncol 30 Suppl. 15 2012 (Abstract 8569)
2. S. Agrawal, Y. Feng, G. Kollia, S. Saeger, M. Ullmann, and D. McDonald Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody J Clin Oncol 30 Suppl. 15 2012 (Abstract TPS2622)
3. S. Ahmad, W. Qian, S.G. Ellis, M.A. Khattak, A. Gupta, and K. Thillai Ipilimumab in the real world: the U.K. expanded access programme (EAP) experience in advanced melanoma J Clin Oncol 31 Suppl. 15 2013 (Abstract 3018)
4. M. Ahmadzadeh, L.A. Johnson, B. Heemskerk, J.R. Wunderlich, M.E. Dudley, and D.E. White Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 114 2009 1537 1544
5. E.A. Akbay, S. Koyama, J. Carretero, A. Altabef, J.H. Tchaicha, and C.L. Christensen Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors Cancer Discov 3 2013 1355 1363
6. M. Altomonte, P. Queirolo, A. Testori, P. Ascierto, R. Danielli, and A.M. Di Giacomo The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients Eur J Cancer 7 Suppl. 2 2009 585 (Abstract 9328)
7. A. Amin, V. DePril, O. Hamid, J. Wolchock, M. Maio, and B. Neyns Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity J Clin Oncol 27 Suppl. 15 2009 (Abstract 9037)
8. A. Amin, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B.I. Rini, and D.F. McDermott Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC) J Clin Oncol 32 Suppl. 5 2014 (Abstract 5010)
9. S.M. Ansell, S.M. Geyer, S. Hurvitz, D. Fernando, T.M. Habermann, and D.J. Inwards Phase I/II study of ipilimumab (MDX-010), an anti-CTLA-4 monoclonal antibody, in patients with follicular non-Hodgkin lymphoma Blood 108 2006 (Abstract 2729)
10. S.M. Ansell, D.W. Northfelt, I. Flinn, H.A. Burris, S.N. Dinner, and V.M. Villalobos Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies J Clin Oncol 32 Suppl. 15 2014 (Abstract 3024)
11. S.J. Antonia, J.R. Brahmer, S.N. Gettinger, L.Q. Man Chow, R.A. Juergens, and F.A. Shepherd Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC) J Clin Oncol 32 Suppl. 5 2014 (Abstract 8113)
12. S.A. Antonia, S.N. Gettinger, L.Q. Man Chow, R.A. Juergens, H. Borghaei, and Y. Shen Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results J Clin Oncol 32 Suppl. 5 2014 (Abstract 8023)
13. C.E. Ariyan, R.A. Lefkowitz, K. Panageas, M.K. Callahan, O. Misholy, and D. Bello Safety and clinical activity of combining systemic ipilimumab with isolated limb infusion in patients with in-transit melanoma J Clin Oncol 32 Suppl. 5 2014 (Abstract 9078)
14. R.J. Armitage Tumor necrosis factor receptor superfamily members and their ligands Curr Opin Immunol 6 1994 407 413
15. P.A. Ascierto, M. Kalos, D.A. Schaer, M.K. Callahan, and J.D. Wolchok Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types Clin Cancer Res 19 2013 1009 1020
16. P. Attia, G.Q. Phan, A.V. Maker, M.R. Robinson, M.M. Quezado, and J.C. Yang Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol 23 2005 6043 6053
17. A. Awada, C.D. Rolfo, S. Rottey, L. Ysebrant de Lendonck, W.A. Schroyens, and F. Offner A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies J Clin Oncol 32 Suppl. 15 2014 (Abstract 3023)
18. A. Bashey, B. Medina, S. Corringham, M. Pasek, E. Carrier, and H. Streicher Phase I study of a neutralizing monoclonal anti-CTLA4 antibody (MDX-010) in patients with relapse of malignancy after allogeneic hematopoietic stem cell transplantation Blood 106 2005 (Abstract 2017)
19. J.E. Bauman, W.E. Gooding, D.A. Clump, S. Kim, B.J. Karlovits, and D.E. Heron Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC) J Clin Oncol 32 Suppl. 5 2014 (Abstract TPS6104)
20. J.-F. Baurain, M. Smylie, P.A. Ascierto, L. Roman, S. Houston, and C. Konto Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial J Clin Oncol 30 Suppl. 15 2012 (Abstract 8539)
21. K.E. Beck, J.A. Blansfield, K.Q. Tran, A.L. Feldman, M.S. Hughes, and R.E. Royal Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 J Clin Oncol 24 2006 2283 2289
22. T.M. Beer, C. Logothetis, W.R. Gerritsen, E.D. Kwon, H.I. Scher, and A. Bossi Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC J Clin Oncol 32 Suppl. 4 2014 (Abstract 52)
23. T.M. Beer, C. Logothetis, P. Sharma, Y. Loriot, K. Fizazi, and A. Bossi CA184-095: a randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC) J Clin Oncol 31 Suppl. 15 2013 (Abstract TPS5093)
24. W. Bensinger, R.T. Maziarz, S. Jagannath, A. Spencer, S. Durrant, and P.S. Becker A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma Br J Haematol 159 2012 58 66
25. R. Berger, R. Rotem-Yehudar, G. Slama, S. Landes, A. Kneller, and M. Leiba Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin Cancer Res 14 2008 3044 3051
26. D. Berman, S.M. Parker, J. Siegel, S.D. Chasalow, J. Weber, and S. Galbraith Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma Cancer Immun 10 2010 11
27. A. Berrocal, J. Valdivia, S.M. Algarra, E. Espinola, T. Curiel, and T. Puertolas Spanish melanoma multidisciplinary group (GEM): long-term survivors treated with ipilimumab in the Expanded Access Program (EAP) Eur J Cancer 49 Suppl. 2 2013 (Abstract 3745)
28. S.B. Bhatia, B.D. Curti, M.S. Gordon, J. Chesney, T. Logan, and J.A. Thompson Phase I dose escalation study of recombinant interleukin-21 (rIL-21, BMS-982470) in combination with ipilimumab (Ipi) in patients (pts) with advanced or metastatic melanoma (MM) J Clin Oncol 31 Suppl. 15 2013 (Abstract TPS3109)
29. J.R. Brahmer, C.G. Drake, I. Wollner, J.D. Powderly, J. Picus, and W.H. Sharfman Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
30. J.R. Brahmer, L. Horn, L. Gandhi, D.R. Spigel, S.J. Antonia, and N.A. Rizvi Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis J Clin Oncol 32 Suppl. 5 2014 (Abstract 8112)
31. J.R. Brahmer, S.S. Tykodi, L.Q.M. Chow, W.-J. Hwu, S.L. Topalian, and P. Hwu Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
32. Bristol-Myers Squibb Phase 3 first-line melanoma study of nivolumab, an investigational PD-1 checkpoint inhibitor, demonstrates superior overall survival compared to dacarbazine; study stopped early 2014 (Press Release June 24)
33. G.R. Brown, K. Meek, Y. Nishioka, and D.L. Thiele CD27-CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes J Immunol 154 1995 3686 3695
34. J.F. Brunet, F. Denizot, M.F. Luciani, M. Roux-Dosseto, M. Suzan, and M.G. Mattei A new member of the immunoglobulin superfamily - CTLA-4 Nature 328 1987 267 270
35. R. Bruno, F. Mercier, and L. Claret Evaluation of tumor size response metrics to predict survival in oncology clinical trials Clin Pharmacol Ther 95 2014 386 393
36. Y. Bulliard, R. Jolicoeur, M. Windman, S.M. Rue, S. Ettenberg, and D.A. Knee Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies J Exp Med 210 2013 1685 1693
37. M.K. Callahan, C.E. Horak, M.A. Curran, T. Hollman, D.A. Schaer, and J. Yuan Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab J Clin Oncol 31 Suppl. 15 2013 (Abstract 3003)
38. M. Callahan, G. Masters, J. Katz, V. Russell, R.A. Roman, and M. Montefusco The immunological impact of the RAF inhibitor BMS908662: preclinical and early clinical experience in combination with CTLA-4 blockade J Clin Oncol 30 Suppl. 15 2012 (Abstract 2521)
39. T. Carre, C. Gaudy-Marqueste, F. Albarel, S. Monestier, S. Mallet, and T. Brue Ipilimumab-induced hypophysitis in melanoma patients J Clin Oncol 30 Suppl. 15 2012 (Abstract 8568)
40. B.C. Carthon, J.D. Wolchok, J. Yuan, A. Kamat, D.S. Ng Tang, and J. Sun Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial Clin Cancer Res 16 2010 2861 2871
41. C.A. Chambers, M.S. Kuhns, J.G. Egen, and J.P. Allison CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy Annu Rev Immunol 19 2001 565 594
42. S. Chandra, K.M. Madden, R. Kannan, and A.C. Pavlick Evaluating the safety of anti-CTLA-4 therapy in the elderly with unresectable melanoma J Clin Oncol 31 Suppl. 15 2013 (Abstract 9063)
43. F. Chasset, C. Pagès, L. Biard, J. Roux, I. Sidina, and I. Madelaine Single-center experience in French Temporary Authorization for Use (TAU) metastatic melanoma program with ipilimumab J Clin Oncol 32 2014 (Suppl., Abstract e20034)
44. M.A. Cheever, and C.S. Higano PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine Clin Cancer Res 17 2011 3520 3526
45. T.-T. Chen Statistical challenges in immuno-oncology BDA Workshop, Frankfurt, January 28-29 2013
46. T.-T. Chen Intermediate endpoints for immune checkpoint modulators: milestone OS analysis FOCR/Brookings Conference on Clinical Cancer Research, Washington, November 7 2013
47. V. Chiarion-Sileni, J. Pigozzo, P.A. Ascierto, M. Maio, R. Danielli, and M. Del Vecchio Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP) J Clin Oncol 31 Suppl. 15 2013 (Abstract 9548)
48. K. Chin, R. Ibrahim, D. Berman, M. Yellin, I. Lowy, and R. Lin Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA-4 therapy Ann Oncol 19 Suppl. 8 2008 (Abstract 787P)
49. T.K. Choueiri, M.N. Fishman, B.J. Escudier, J.J. Kim, H.M. Kluger, and W.M. Stadler Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial J Clin Oncol 32 Suppl. 5 2014 (Abstract 5012)
50. ClinicalTrials.gov A phase 1, multicenter, open-label study to evaluate the safety, tolerability, and pharmacokinetics of MEDI0680 (AMP-514) in subjects with advanced malignancies Retrieved from https://clinicaltrials.gov/ct2/show/NCT02013804
51. ClinicalTrials.gov Safety study of anti-LAG-3 with and without anti-PD-1 in the treatment of solid tumors Retrieved from https://clinicaltrials.gov/ct2/show/NCT01968109
52. ClinicalTrials.gov A phase 1 study of MEDI6383 in adult subjects with select advanced solid tumors Retrieved from https://clinicaltrials.gov/ct2/show/NCT02221960
53. ClinicalTrials.gov Study of MK-4166 in participants with advanced solid tumors (MK-4166-001) Retrieved from https://clinicaltrials.gov/ct2/show/NCT02132754
54. ClinicalTrials.gov A phase 1 dose escalation study of MGA271 in refractory cancer Retrieved from https://clinicaltrials.gov/ct2/show/NCT01391143
55. ClinicalTrials.gov An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapy Retrieved from https://clinicaltrials.gov/ct2/show/NCT01585987
56. ClinicalTrials.gov Phase II study of ipilimumab monotherapy in recurrent platinum sensitive ovarian cancer patients Retrieved from https://clinicaltrials.gov/ct2/show/NCT01611558
57. ClinicalTrials.gov Phase 2, randomized, double blinded, study of nivolumab (BMS-936558) in combination with ipilimumab vs ipilimumab alone in subjects with previously untreated, unresectable or metastatic melanoma (CheckMate 069) Retrieved from https://clinicaltrials.gov/ct2/show/NCT01927419
58. ClinicalTrials.gov Phase 3 study of nivolumab or nivolumab plus ipilimumab versus ipilimumab alone in previously untreated advanced melanoma (CheckMate 067) Retrieved from https://clinicaltrials.gov/ct2/show/NCT01844505
59. ClinicalTrials.gov Phase 3 trial in subjects with metastatic melanoma comparing 3 mg/kg ipilimumab versus 10 mg/kg ipilimumab Retrieved from https://clinicaltrials.gov/ct2/show/NCT01515189
60. ClinicalTrials.gov Ipilimumab or high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery Retrieved from https://clinicaltrials.gov/ct2/show/NCT01274338
61. M.A. Curran, W. Montalvo, H. Yagita, and J.P. Allison PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc Natl Acad Sci U S A 107 2010 4275 4280
62. D. Dai, C. Wu, S.M. Parker, M.N. Jure-Kunkel, M. Pfister, and D. Berman Model-based evaluation of ipilimumab dosage regimen in patients with advanced melanoma J Clin Oncol 26 Suppl. 15 2008 (Abstract 9073)
63. R. Danielli, R. Ridolfi, V. Chiarion-Sileni, P. Queirolo, A. Testori, and R. Plummer Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy Cancer Immunol Immunother 61 2012 41 48
64. A.I. Daud, O. Hamid, A. Ribas, F.S. Hodi, W.-J. Hwu, and R. Kefford Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma (MEL): correlation of tumor PD-L1 expression with outcome Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; April 5-9; San Diego, CA. Abstract CT104 2014
65. J. Delyon, C. Mateus, and F.T. Lambert Hemophilia A induced by ipilimumab N Engl J Med 365 2011 1747 1748
66. S. Demaria, N. Kawashima, A.M. Yang, M.L. Devitt, J.S. Babb, and J.P. Allison Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer Clin Cancer Res 11 2005 728 734
67. M.A. Deo J Clin Oncol 32 Suppl. 15 2014 (Abstract 30)
68. A.M. Di Giacomo, P.A. Ascierto, L. Pilla, M. Santinami, P.F. Ferrucci, and D. Giannarelli Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial Lancet Oncol 13 2012 879 886
69. A.M. Di Giacomo, A.M. Grimaldi, P.A. Ascierto, P. Queirolo, M. Del Vecchio, and R. Ridolfi Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP) J Clin Oncol 31 Suppl. 15 2013 (Abstract 9065)
70. A. Diab, H.L. McArthur, S.B. Solomon, V. Sacchini, C. Comstock, and M. Maybody A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC) J Clin Oncol 32 Suppl. 5 2014 (Abstract 1098)
71. T. Dillard, C.G. Yedinak, J. Alumkal, and M. Fleseriu Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes Pituitary 13 2010 29 38
72. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, and D. Flies Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
73. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 1999 1365 1369
74. S.G. Downey, J.A. Klapper, F.O. Smith, J.C. Yang, R.M. Sherry, and R.E. Royal Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade Clin Cancer Res 13 2007 6681 6688
75. C.G. Drake, D.F. McDermott, M. Sznol, T.K. Choueiri, H.M. Kluger, and J.D. Powderly Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up J Clin Oncol 31 Suppl. 15 2013 (Abstract 4514)
76. Drugs@FDA (2014). Downloaded September 1, 2014.
77. J. Dubrot, F. Milheiro, C. Alfaro, A. Palazón, I. Martinez-Forero, and J.L. Perez-Gracia Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ Cancer Immunol Immunother 59 2010 1223 1233
78. A.M. Eggermont, V. Chiarion-Sileni, J.J. Grob, R. Dummer, J.D. Wolchok, and H. Schmidt Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial J Clin Oncol 32 Suppl. 18 2014 (Abstract LBA9008)
79. EMA Guidance on the evaluation of anticancer medicinal products in man 2012 (Issued December 13, 2012)
80. F. Fadel, K. El Karoui, and B. Knebelmann Anti-CTLA4 antibody-induced lupus nephritis N Engl J Med 361 2009 211 212
81. FDA/CBER Guidance for Industry - Clinical considerations for therapeutic cancer vaccines 2011 (Issued October 2011)
82. Y. Feng, S. Agrawal, M. Gupta, A.K. Gupta, E. Masson, and A. Roy Association between immune-checkpoint inhibitor induced tumor shrinkage and overall survival in advanced melanoma and NSCLC J Clin Oncol 32 Suppl. 15 2014 (Abstract 3053)
83. F.Y. Feng, C.J. Godfrey, H.-M. Chu, E. Masson, D. Williams, and D.M. Berman Characterization of ipilimumab exposure-efficacy/safety response relationships in subjects with previously treated or untreated advanced melanoma J Clin Oncol 30 Suppl. 15 2012 (Abstract 8541)
84. Y. Feng, E. Masson, D. Williams, J. Song, J.-M. Cuillerot, and A. Roy Characterization of the relationship between ipilimumab exposure, tumor size, and survival in previously treated non-small cell lung cancer patients 113th American Society for Clinical Pharmacology and Therapeutics Annual Meeting, National Harbor, March 12-17 2012 (Abstract 253)
85. L. Fong, E. Cha, M. Klinger, Y. Hou, C. Cummings, and R. Ribas Association of maintenance of pre-existing memory T-cell responses following anti-CTLA-4 antibody treatment with improved overall survival J Clin Oncol 32 Suppl. 5 2014 (Abstract 3016)
86. G.J. Freeman, A.J. Long, Y. Iwai, K. Bourque, T. Chernova, and H. Nishimura Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
87. S.N. Gettinger, F.A. Shepherd, S.J. Antonia, J.R. Brahmer, L.Q. Man Chow, and R.A. Juergens First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status J Clin Oncol 32 Suppl. 5 2014 (Abstract 8024)
88. G.T. Gibney, O. Hamid, T.C. Gangadhar, J. Lutzky, A.J. Olszanski, and T. Gajewski Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma J Clin Oncol 32 Suppl. 15 2014 (Abstract 3010)
89. G.T. Gibney, J.S. Weber, R.R. Kudchadkar, R.C. De Conti, L. Tetteh, and C. Eysmans Safety and efficacy of adjuvant anti-PD1 therapy (nivolumab) in combination with vaccine in resected high-risk metastatic melanoma J Clin Oncol 31 Suppl. 15 2013 (Abstract 9056)
90. M.S. Gordon, O. Hamid, J. Powderly, M. Anderson, G. Fine, and A. Mokatrin A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors Cancer Res 73 Supplement 1 2013 (Abstract LB-288)
91. C.F. Granberg, R.J. Karnes, M.K. Tollefson, R.H. Thompson, J.P. Allison, and T.J. Sebo Conversion of advanced prostate cancer to organ-confined minimal residual disease using CTLA-4 blockade (ipilimumab) immunotherapy ASCO 2010 Genitourinary Cancers Symposium, San Francisco, March 5-7, Abstract 33 2010
92. J.M. Green, P.J. Noel, A.I. Sperling, T.L. Walunas, G.S. Gray, and J.A. Bluestone Absence of B7-dependent responses in CD28-deficient mice Immunity 1 1994 501 508
93. J.F. Grosso, M.V. Goldberg, D. Getnet, T.C. Bruno, H.-R. Yen, and K.J. Pyle Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells J Immunol 182 2009 6659 6669
94. J. Grosso, C.E. Horak, D. Inzunza, D.M. Cardona, J.S. Simon, and A.K. Gupta Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) J Clin Oncol 31 Suppl. 15 2013 (Abstract 3016)
95. J.F. Grosso, and M.N. Jure-Kunkel CTLA-4 blockade in tumor models: an overview of preclinical and translational research Cancer Immun 13 2013 5 18
96. J.F. Grosso, C.C. Kelleher, T.J. Harris, C.H. Maris, E.L. Hipkiss, and A. De Marzo LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems J Clin Invest 117 2007 3383 3392
97. J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, and N. Matsumura Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer J Clin Oncol 32 Suppl. 5 2014 (Abstract 5511)
98. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.-J. Hwu, and R. Kefford Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2013 134 144
99. O. Hamid, H. Schmidt, A. Nissan, L. Ridolfi, S. Aamdal, and J. Hansson A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma J Transl Med 9 2011 204 219
100. H.J. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B.I. Rini, and D.F. McDermott Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) J Clin Oncol 32 Suppl. 5 2014 (Abstract 4504)
101. A.L. Harzstark, L. Fong, V.K. Weinberg, C.J. Ryan, A.M. Lin, and J. Sun Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC) J Clin Oncol 28 Suppl. 15 2010 (Abstract 4689)
102. C.R. Heery, G.H. O'Sullivan Coyne, R.A. Madan, J. Schlom, A. von Heydebreck, and J.-M. Cuillerot Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies J Clin Oncol 32 Suppl. 15 2014 (Abstract 3064)
103. J. Hendriks, L.A. Gravestein, K. Tesselaar, R.A.W. Van Lier, T.N.M. Schumacher, and J. Borst CD27 is required for generation and long-term maintenance of T cell immunity Nat Immunol 1 2000 433 440
104. E.M. Hersh, S.J. O'Day, J. Powderly, K.D. Khan, A.C. Pavlick, and L.D. Cranmer A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma Invest New Drugs 29 2011 489 498
105. C. Higano, F. Saad, B. Somer, B. Curti, D. Petrylak, and C.G. Drake A phase III trial of GVAX immunotherapy for prostate cancer vs. docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) ASCO 2009 Genitourinary Cancers Symposium, Orlando, February 26-28, Abstract 150 2009
106. F.S. Hodi, P.A. Friedlander, M.B. Atkins, D.F. McDermott, D.P. Lawrence, and N. Ibrahim A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma J Clin Oncol 29 Suppl. 15 2011 (Abstract 8511)
107. F.S. Hodi, S.J. Lee, D.F. McDermott, U.N.M. Rao, L.H. Butterfield, and A.A. Tarhini Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608 J Clin Oncol 31 Suppl. 15 2013 (Abstract CRA9007)
108. F.S. Hodi, M.C. Mihm, R.J. Soiffer, F.G. Haluska, M. Butler, and M.V. Seiden Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci U S A 100 2003 4712 4717
109. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
110. F.S. Hodi, M. Sznol, H.M. Kluger, D.F. McDermott, R.D. Carvajal, and D.P. Lawrence Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial J Clin Oncol 32 Suppl. 5 2014 (Abstract 9002)
111. F.S. Hodi, S.L. Topalian, J.R. Brahmer, D.F. McDermott, D.C. Smith, and S. Gettinger Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538) Eur J Cancer 49 Suppl. 2 2013 (Abstract 880)
112. A. Hoos, A.M.M. Eggermont, S. Janetzki, F.S. Hodi, R. Ibrahim, and A. Anderson Improved endpoints for cancer immunotherapy trials J Natl Cancer Inst 102 2010 1388 1397
113. A. Hoos, R. Ibrahim, A. Korman, K. Abdallah, D. Berman, and V. Shahabi Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy Semin Oncol 37 2010 533 546
114. R.S. Hotchkiss, and L.L. Moldawer Parallels between cancer and infectious disease N Engl J Med 371 2014 380 383
115. J.L. Hu, P. Sharma, J. Yu, K.L. Black, and J.D. Rudnick Ipilimumab for recurrent glioblastoma: a single-institution case series J Clin Oncol 32 2014 (Suppl., Abstract e13010)
116. B. Huard, P. Prigent, M. Tournier, D. Bruniquel, and F. Triebel CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-ig fusion proteins Eur J Immunol 25 1995 2718 2721
117. A.A. Hurwitz, B.A. Foster, E.D. Kwon, T. Truong, E.M. Choi, and N.M. Greenberg Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade Cancer Res 60 2000 2444 2448
118. R.A. Ibrahim, D.M. Berman, V. DePril, R.W. Humphrey, T. Chen, and M. Messina Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma J Clin Oncol 29 Suppl. 15 2011 (Abstract 8583)
119. J.R. Infante, H.A. Burris, S.M. Ansell, J.J. Nemunaitis, G.R. Weiss, and V.M. Villalobos Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors J Clin Oncol 32 Suppl. 15 2014 (Abstract 3027)
120. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 11 1992 3887 3895
121. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci U S A 99 2002 12293 12297
122. S. Iwama, A. De Remigis, M.K. Callahan, S.F. Slovin, J.D. Wolchok, and P. Caturegli Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody Sci Transl Med 6 2014 1 11
123. S.H. Jaber, E.W. Cowen, L.R. Haworth, S.L. Booher, D.M. Berman, and S.A. Rosenberg Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent Arch Dermatol 142 2006 166 172
124. R. Jamal, K. Belanger, J.E. Friedmann, J.-P.M. Ayoub, E. Cocolakis, and S. Kazemi A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM) J Clin Oncol 32 Suppl. 5 2014 (Abstract 9066)
125. D.B. Johnson, C. Peng, R.G. Abramson, J.D. Wolchok, J.A. Sosman, and R.D. Carvajal Ipilimumab in acral melanoma: a retrospective review J Clin Oncol 32 Suppl. 15 2014 (Abstract 9056)
126. D.B. Johnson, V. Saranga-Perry, P.J.M. Lavin, W.B. Burnette, S.W. Clark, and D.R. Uskavitch Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma J Clin Oncol 2014 (epub ahead of print)
127. P.W. Johnson, N.M. Steven, F. Chowdhury, J. Dobbyn, E. Hall, and M. Ashton-Key A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4 J Clin Oncol 28 Suppl. 15 2010 (Abstract 2507)
128. R.W. Joseph, P. Hwu, M.A. Davies, M.B. Atkins, and R.J. Sullivan Clinical benefit of ipilimumab in patients with metastatic melanoma who progress on high-dose IL-2 J Clin Oncol 29 Suppl. 15 2011 (Abstract 8537)
129. T. Keler, E. Halk, L. Vitale, T. O'Neill, D. Blanset, and S. Lee Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques J Immunol 171 2003 6251 6259
130. S. Khubchandani, M.S. Czuczman, and F.J. Hernandez-Ilizaliturri Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies Curr Opin Investig Drugs 10 2009 579 587
131. D.E. Kleiner, and D. Berman Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma Dig Dis Sci 57 2012 2233 2240
132. H.E. Kohrt, J.E. Godwin, I.S. Lossos, M.E. Williams, J. Timmerman, and B.K. Link A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies J Clin Oncol 31 2013 (Suppl., Abstract TPS3108)
133. H.E. Kohrt, R. Houot, K. Weiskopf, M. Goldstein, P. Lund, and F. Scheeren Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab J Clin Oncol 30 Suppl. 15 2012 (Abstract 2514)
134. A. Korman, B. Chen, C. Wang, L. Wu, P. Cardarelli, and M. Selby Activity of anti-PD-1 in murine tumor models: role of "host" PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4 J Immunol 178 2007 (Abstract 48.37)
135. M.F. Krummel, and J.P. Allison CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation J Exp Med 182 2 1995 459 465
136. R.R. Kudchadkar, D. Gallenstein, A.J. Martinez, B. Yu, and J.S. Weber Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma J Clin Oncol 30 Suppl. 15 2012 (Abstract 8582)
137. R.R. Kudchadkar, G.T. Gibney, D. Dorman, S. Merek, H. Ramadan, and A. Chen A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma J Clin Oncol 32 Suppl. 5 2014 (Abstract 9098)
138. E.D. Kwon, C.G. Drake, H.I. Scher, K. Fizazi, A. Bossi, and A.J. van den Eertwegh Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Lancet Oncol 15 2014 700 712
139. Y. Latchman, C.R. Wood, T. Chernova, D. Chaudhary, M. Borde, and I. Chernova PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 2001 261 268
140. C. Lebbe, S.J. O'Day, V. Chiarion Sileni, T.F. Gajewski, H. Pehumberger, and I.N. Bondarenko Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma Perspectives in Melanoma XII, Amsterdam, October 2-4, Abstract O.015 2008
141. C. Lebbé, J.S. Weber, M. Maio, B. Neyns, K. Harmankaya, and O. Hamid Survival follow-up and ipilimumab retreatment for patients with advanced melanoma who received ipilimumab in prior in phase II studies Ann Oncol 25 2014 2277 2284
142. R.M. Lee-Ying, X. Feng, M. Smylie, J.G. Monzon, and T. Cheng Efficacy of two ipilimumab (IPI) doses (10 vs. 3 mg/kg) in Alberta, Canada, tertiary cancer centers J Clin Oncol 32 Suppl. 5 2014 (Abstract 9090)
143. S.Y. Li, and Y. Liu Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137 Clin Pharmacol 5 Suppl. 1 2013 47 53
144. F. Li, and J.V. Ravetch Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo Proc Natl Acad Sci U S A 110 2013 19501 19506
145. P.S. Linsley, W. Brady, L. Grosmaire, A. Aruffo, N.K. Damle, and J.A. Ledbetter Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation J Exp Med 173 1991 721 730
146. P.S. Linsley, W. Brady, M. Urnes, L.S. Grosmaire, N.K. Damle, and J.A. Ledbetter CTLA-4 is a second receptor for the B cell activation antigen B7 J Exp Med 174 1991 561 565
147. E.J. Lipson, W.H. Sharfman, C.G. Drake, I. Wollner, J.M. Taube, and R.A. Anders Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody Clin Cancer Res 19 2013 462 468
148. T. Logan, F.S. Hodi, K. Margolin, D.F. McDermott, M.S. Ernstoff, and J.M. Kirkwood Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (Pts) with advanced cancer (CA) J Immunother 31 2008 (Abstract P101)
149. M. Loos, D.M. Hedderich, H. Friess, and J. Kleeff B7-H3 and its role in antitumor immunity Clin Dev Immunol 2010 2010 1 7 10.1155/2010/683875
150. P. Lorigan, J.A. Sosman, J.B. Haanen, J. Lutzky, D. Hogg, and M. Gore Clinical response to ipilimumab: effect of systemic corticosteroids used to manage immune-related adverse events (IRAES Ann Oncol 21 Suppl. 8 2010 (Abstract 1331P)
151. J.J. Luke, M.K. Callahan, M.A. Postow, E. Romano, N. Ramaiya, and M. Bluth Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience Cancer 119 2013 3687 3695
152. J. Lutzky, S.J. Antonia, A. Blake-Haskins, X. Li, P.B. Robbins, and A.M. Shalabi A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors J Clin Oncol 32 Suppl. 15 2014 (Abstract 3001)
153. J. Lutzky, J. Wolchok, O. Hamid, C. Lebbe, H. Pehamberger, and G. Linette Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials J Clin Oncol 27 Suppl. 15 2009 (Abstract 9034)
154. T.J. Lynch, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, and R. Chacko Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 2012 2046 2054
155. R.A. Madan, M. Mohebtash, P.M. Arlen, M. Vergati, M. Rauckhorst, and S.M. Steinberg Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial Lancet Oncol 13 2012 501 508
156. M. Maio, I. Bondarenko, C. Robert, L. Thomas, C. Garbe, and A. Testori Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma Eur J Cancer 49 Suppl. 2 2013 (Abstract 3704)
157. A.V. Maker, G.Q. Phan, P. Attia, J.C. Yang, R.M. Sherry, and S.L. Topalian Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study Ann Surg Oncol 12 2005 1005 1016
158. A.V. Maker, J.C. Yang, R.M. Sherry, S.L. Topalian, U.S. Kammula, and R.E. Royal Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma J Immunother 29 2006 455 463
159. K. Margolin, M.S. Ernstoff, O. Hamid, D. Lawrence, D. McDermott, and I. Puzanov Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol 13 2012 459 465
160. K.A. Margolin, O. Hamid, J.S. Weber, A.C. Pavlick, F.S. Hodi, and A. Amin Ipilimumab retreatment following induction therapy: the expanded access program (EAP) experience J Clin Oncol 31 Suppl. 15 2013 (Abstract 9041)
161. K. Margolin, S.L. Wong, J.R. Penrod, J. Song, I. Chang, and T. Hebden Effectiveness and safety of first-line ipilimumab (IPI) 3 mg/kg therapy for advanced melanoma (AM): evidence from a U.S. multisite retrospective chart review Eur J Cancer 49 Suppl. 2 2013 (Abstract 3742)
162. G. Masters, L. Barreto, E. Girit, and M. Jure-Kunkel Antitumor activity of cytotoxic T-lymphocyte antigen-4 blockade alone or combined with paclitaxel, etoposide, or gemcitabine in murine models J Immunother 32 2009 994
163. D. McDermott, J. Haanen, T.-T. Chen, P. Lorigan, and S. O'Day Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20) Ann Oncol 24 2013 2694 2698
164. I. Melero, N. Bach, K.E. Hellström, A. Aruffo, R.S. Mittler, and L. Chen Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway Eur J Immunol 28 1998 1116 1121
165. I. Melero, T.C. Gangadhar, H.E. Kohrt, N.H. Segal, T. Logan, and W.J. Urba A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) J Clin Oncol 31 Suppl. 15 2013
166. I. Melero, A.M. Grimaldi, J.L. Perez-Gracia, and P.A. Ascierto Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination Clin Cancer Res 19 2013 997 1008
167. I. Melero, W.W. Shuford, S.A. Newby, A. Aruffo, J.A. Ledbetter, and K.E. Hellström Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors Nat Med 3 1997 682 685
168. M.S. Merchant, K. Baird, L.H. Wexler, C. Rodriguez-Galindo, and C. Mackall Clin Oncol 30 Suppl. 15 2012 (Abstract 9545)
169. J. Moser, J. Pulido, R.S. Dronca, S. Markovic, and A.S. Mansfield The Mayo Clinic experience with the use of kinase inhibitors (KIs), ipilimumab, and bevacizumab in the treatment of metastatic ocular melanoma J Clin Oncol 32 Suppl. 15 2014
170. R.J. Motzer, B.I. Rini, D.F. McDermott, B.G. Redman, T. Kuzel, and M.R. Harrison Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial J Clin Oncol 32 Suppl. 5 2014 (Abstract 5009)
171. B. Neyns, J.S. Weber, C. Lebbé, M. Maio, K. Harmankaya, and O. Hamid Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials J Clin Oncol 31 Suppl. 15 2013 (Abstract 9059)
172. H. Nokihara, H. Horinouchi, S. Yagishita, S. Kitazono, H. Mizugaki, and S. Kanda Phase 1 study of ipilimumab in combination with paclitaxel/carboplatin in patients with non-small cell lung cancer J Thorac Oncol 8 Suppl. 2 2013 S911 (Abstract P2.11-040)
173. S.J. O'Day, M. Maio, V. Chiarion-Sileni, T.F. Gajewski, H. Pehamberger, and I.N. Bondarenko Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study Ann Oncol 21 2010 1712 1717
174. T.K. Owonikoko, A. Hussain, W.M. Stadler, D.C. Smith, M. Sznol, and A.M. Molina A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL) J Clin Oncol 32 Suppl. 15 2014 (Abstract 2558)
175. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
176. S.P. Patel, W.-J. Hwu, K.B. Kim, N.E. Papadopoulos, P. Hwu, and L.G. Radvanyi Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma J Clin Oncol 30 Suppl. 15 2012 (Abstract 8514)
177. D. Patt, S.L. Wong, T. Juday, J.R. Penrod, C. Chen, and T. Hebden A community-based, real-world, study of treatment-naive advanced melanoma (AM) patients treated with 3 mg/kg ipilimumab (IPI) in the United States Eur J Cancer 49 Suppl. 2 2013 (Abstract 3751)
178. A.C. Pavlick, S. Chandra, C. Stein, K.M. Madden, R. Kannan, and C. Escano Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma J Clin Oncol 32 2014 (Suppl., Abstract e20025
179. K.S. Peggs, S.A. Quezada, C.A. Chambers, A.J. Korman, and J.P. Allison Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies J Exp Med 206 2009 1717 1725
180. G.Q. Phan, J.C. Yang, R.M. Sherry, P. Hwu, S.L. Topalian, and D.J. Schwartzentruber Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sci U S A 100 2003 8372 8377
181. J.M. Piulats Rodriguez, M. Ochoa de Olza, M. Codes, J.A. Lopez-Martin, A. Berrocal, and M. García Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): the GEM-1 trial J Clin Oncol 32 Suppl. 15 2014 (Abstract 9033)
182. K.E. Pollok, Y.-J. Kim, Z. Zhou, J. Hurtado, K.K. Kim, and R.T. Pickard Inducible T cell antigen 4-1BB: analysis of expression and function J Immunol 150 1993 771 781
183. J.D. Powderly, H. Koeppen, F.S. Hodi, J.A. Sosman, S.N. Gettinger, and R. Desai Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study J Clin Oncol 31 Suppl. 15 2013 (Abstract 3001)
184. P.A. Prieto, J.C. Yang, R.M. Sherry, M.S. Hughes, U.S. Kammula, and D.E. White CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma Clin Cancer Res 18 2012 2039 2047
185. I. Puzanov, M.K. Callahan, G.P. Linette, S.P. Patel, J.J. Luke, and J.A. Sosman Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) J Clin Oncol 32 Suppl. 5 2014 (Abstract 2511)
186. I. Puzanov, M.M. Milhem, R.H.I. Andtbacka, D.R. Minor, O. Hamid, and A. Li Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma J Clin Oncol 32 Suppl. 5 2014 (Abstract 9029)
187. P. Queirolo, A. Morabito, P. Piccioli, S. Lastraioli, S. Callegari, and M. Camoriano Analysis of CTLA-4 gene polymorphisms in patients with advanced melanoma treated with anti-CTLA-4 therapy J Clin Oncol 29 Suppl. 15 2011 (Abstract 8588)
188. P. Queirolo, F. Spagnolo, M. Altomonte, V. Chiarion-Sileni, J. Pigozzo, and M. Del Vecchio Italian cohort of ipilimumab expanded access programme (EAP): efficacy, safety, and correlation with mutation status in metastatic melanoma patients J Clin Oncol 31 Suppl. 15 2013 (Abstract 9070)
189. M. Reck, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, and R. Chacko Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Ann Oncol 24 2013 75 83
190. A. Ribas, L.H. Camacho, G. Lopez-Berestein, D. Pavlov, C.A. Bulanhagui, and R. Millham Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206 J Clin Oncol 23 2005 8968 8977
191. A. Ribas, F.S. Hodi, M. Callahan, C. Konto, and J. Wolchok Hepatotoxicity with combination of vemurafenib and ipilimumab N Engl J Med 368 2013 1365 1366
192. J. Richards, P. Hwu, K. Chin, R. Ibrahim, D. Berman, and M.J. Yellin Evaluation of treatment guidelines developed for management of immune-related adverse events in ipilimumab clinical protocols Perspectives in Melanoma XIII, Baltimore, October 8-10, Abstract 0-0006 2009
193. N.A. Rizvi, L.Q. Man Chow, H. Borghaei, Y. Shen, C. Harbison, and S. Alaparthy Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC J Clin Oncol 32 Suppl. 5 2014 (Abstract 8022)
194. C. Robert, F.S. Hodi, S.J. O'Day, C. Peschel, C.H. Ottensmeier, and U. Trefzer Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both in a phase III study of previously-treated patients with advanced melanoma: update of clinical characteristics of patients Ann Oncol 21 2010 (Suppl., Abstract 1330P)
195. C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, and C. Garbe Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
196. M. Rosenzweig, J. Ponte, I. Apostolou, D. Doty, J. Guild, and M. Slavonic Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR J Clin Oncol 28 Suppl. 15 2010 (Abstract e13028)
197. R.E. Royal, C. Levy, M. Hughes, U. Kammula, R. Sherry, and J. Yang Phase II trial of single-agent ipilimumab (anti-CTLA4) for locally advanced or metastatic pancreatic adenocarcinoma: delayed response in a single patient ASCO 2009 Gastrointestinal Cancers Symposium, San Francisco, January 15-17, Abstract 153 2009
198. E. Ruffini, S. Asioli, P.L. Filosso, P. Lyberis, M.C. Bruna, and L. Macrì Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms Ann Thorac Surg 87 2009 365 372
199. K. Sanderson, R. Scotland, P. Lee, D. Liu, S. Groshen, and J. Snively Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma J Clin Oncol 23 4 2005 741 750
200. A.A. Sarnaik, B. Yu, D. Yu, D. Morelli, M. Hall, and D. Bogle Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma Clin Cancer Res 17 2011 896 906
201. D. Schadendorf, J. Wolchok, B. Neyns, C. Lebbé, K. Harmankaya, and C. Verschraegen Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors Eur J Cancer Supplements 7 2009 579 l(Abstract 9308)
202. L.R. Schaff, A.B. Lassman, S.A. Goldlust, T.F. Cloughesy, S. Singer, and G.K. Schwartz Ipilimumab for recurrent glioblastoma (GBM) J Clin Oncol 32 Suppl. 15 2014 (Abstract e13026)
203. R. Schmerling, D. Herchenhorn, J.A. Rinck, V.P. De Camargo, J. Camargo, and S.V. Serrano Ipilimumab for stage unresectable III/IV melanoma: Brazilian experience in an expanded access program J Clin Oncol 32 Suppl. 15 2014 (Abstract e20045)
204. N.H. Segal, A.K. Gopal, S. Bhatia, H.E. Kohrt, R. Levy, and M.J. Pishvaian A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer J Clin Oncol 32 Suppl. 15 2014 (Abstract 3007)
205. M. Selby, J. Engelhardt, L.-S. Lu, M. Quigley, C. Wang, and B. Chen Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models J Clin Oncol 31 Suppl. 15 2013 (Abstract 3061)
206. M.J. Selby, J.J. Engelhardt, M. Quigley, K.A. Henning, T. Chen, and M. Srinivasan Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells Cancer Immunol Res 1 2013 32 42
207. V. Shahabi, G. Whitney, O. Hamid, H. Schmidt, S.D. Chasalow, and S. Alaparthy Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab Cancer Immunol Immunother 61 2012 733 737
208. F.A. Shepherd, J.-Y. Douillard, and G.R. Blumenschein Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome J Thorac Oncol 6 2011 1763 1773
209. S. Shoukat, D.M. Marcus, M. Rizzo, D.H. Lawson, Y. Liu, and M.K. Khan Outcome with stereotactic radiosurgery (SRS) and ipilimumab (Ipi) for malignant melanoma brain metastases J Clin Oncol 31 Suppl. 15 2013 (Abstract 3032)
210. A.N. Shoushtari, S.P. D'Angelo, M.L. Keohan, M.A. Dickson, M.M. Gounder, and A.K. Abdullah Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas J Clin Oncol 32 Suppl. 5 2014 (Abstract 10521)
211. T.R. Simpson, F. Li, W. Montalvo-Ortiz, M.A. Sepulveda, K. Bergerhoff, and F. Arce Fc-dependent depletion of tumor-infiltrating regulatory t cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma J Exp Med 210 2013 1695 1710
212. S.F. Slovin, C.S. Higano, O. Hamid, S. Tejwani, A. Harzstark, and J.J. Alumkal Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Ann Oncol 24 2013 1813 1821
213. E. Small, T. Demkow, W.R. Gerritsen, F. Rolland, P. Hoskin, and D.C. Smith A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) ASCO 2009 Genitourinary Cancers Symposium, Orlando, Florida, February 26-28, Abstract 7 2009
214. E. Small, C. Higano, N. Tchekmedyian, O. Sartor, B. Stein, and R. Young Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer J Clin Oncol 24 Suppl. 18 2006 (Abstract 4609)
215. E.J. Small, N.S. Tchekmedyian, B.I. Rini, L. Fong, I. Lowy, and J.P. Allison A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 2007 1810 1815
216. F. Smothers, A. Hoos, S. Langerman, S. Marshall, R. May, and M. Fleming AMP-224, a fusion protein that targets PD-1 Ann Oncol 24 Suppl. 1 2013 i7 (Abstract L02 04)
217. M. Smylie, S. Francis, B. Neyns, M. Maio, D. Minor, and C. Verschraegen Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels J Clin Oncol 27 Suppl. 15 2009 (Abstract 9041)
218. C. Suzuki, L. Blomqvist, A. Sundin, H. Jacobsson, P. Byström, and Å. Berglund The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy Ann Oncol 23 2012 948 954
219. M. Sznol, F.S. Hodi, K. Margolin, D.F. McDermott, M.S. Ernstoff, and J.M. Kirkwood Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) J Clin Oncol 26 Suppl. 15 2008 (Abstract 3007)
220. M. Sznol, H.M. Kluger, M.K. Callahan, M.A. Postow, R.A. Gordon, and N.H. Segal Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) J Clin Oncol 32 Suppl. 5 2014 (Abstract LBA9003)
221. S. Tchekemedyian, J. Glasby, A. Korman, T. Keler, Y. Deo, and T.A. Davis MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma J Clin Oncol 21 2002 15a (Suppl., Abstract 56)
222. L. Thomas, J.D. Wolchok, C. Garbe, C. Lebbe, I. Bondarenko, and K. Rodrigues Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: results from a phase III study J Clin Oncol 30 Suppl. 15 2012 (Abstract 8512)
223. J.A. Thompson, O. Hamid, D. Minor, A. Amin, I.G. Ron, and R. Ridolfi Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial J Immunother 35 2012 73 77
224. E.A. Tivol, F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. Bluestone, and A.H. Sharpe Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 3 1995 541 547
225. M.K. Tollefson, R.J. Karnes, R.H. Thompson, C.F. Granberg, D.W. Hillman, and R.H. Breau A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer ASCO 2010 Genitourinary Cancers Symposium, San Francisco, March 5-7, Abstract 168 2010
226. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, and D.F. McDermott Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
227. S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, and W.H. Sharfman Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 2014 1020 1030
228. F. Triebel, S. Jitsukawa, E. Baixeras, S. Roman-Roman, C. Genevee, and E. Viegas-Pequignot LAG-3, a novel lymphocyte activation gene closely related to CD4 J Exp Med 171 1990 1393 1405
229. S.-Y. Tseng, M. Otsuji, K. Gorski, X. Huang, J.E. Slansky, and S.I. Pai B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells J Exp Med 193 2001 839 845
230. A.J.M. Van den Eertwegh, J. Versluis, H.P. Van den Berg, S.J.A.M. Santegoets, R.J.A. Van Moorselaar, and T.M. Van der Sluis Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial Lancet Oncol 13 2012 509 517
231. W.V. Vogel, A. Guislain, P. Kvistborg, T.N.M. Schumacher, J.B.A.G. Haanen, and C.U. Blank Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission J Clin Oncol 30 2 2012 e7 e10
232. R.H. Vonderheide, K.T. Flaherty, M. Khalil, M.S. Stumacher, D.L. Bajor, and N.A. Hutnick Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody J Clin Oncol 25 2007 876 883
233. T.L. Walunas, D.J. Lenschow, C.Y. Bakker, P.S. Linsley, G.J. Freeman, and J.M. Green CTLA-4 can function as a negative regulator of T cell activation Immunity 1 1994 405 441
234. Y. Wang, C. Sung, C. Dartois, R. Ramchandani, B.P. Booth, and E. Rock Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development Clin Pharm Ther 86 2009 167 174
235. C. Wang, K.B. Thudium, M. Han, X.-T. Wang, H. Huang, and D. Feingersh In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates Cancer Immunol Res 2 2014 1 11
236. P. Waterhouse, J.M. Penninger, E. Timms, A. Wakeham, A. Shahinian, and K.P. Lee Lymphoproliferative disorders with early lethality in mice deficient in ctla-4 Science 270 1995 985 988
237. J.S. Weber, A. Amin, D. Minor, J. Siegel, D. Berman, and S.J. O'Day Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial Melanoma Res 21 2011 530 534
238. J. Weber, O. Hamid, A. Amin, S. O'Day, E. Masson, and S.M. Goldberg Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma Cancer Immun 13 2013 7 16
239. J.S. Weber, R.R. Kudchadkar, B. Yu, D. Gallenstein, C.E. Horak, and H.D. Inzunza Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma J Clin Oncol 31 2013 4311 4318
240. J.S. Weber, S. O'Day, W. Urba, J. Powderly, G. Nichol, and M. Yellin Phase I/II study of ipilimumab for patients with metastatic melanoma J Clin Oncol 26 2008 5950 5956
241. J. Weber, J.A. Thompson, O. Hamid, D. Minor, A. Amin, and I. Ron A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma Clin Cancer Res 15 2009 5591 5598
242. A.D. Weinberg, C. Thalhofer, N. Morris, J.M. Walker, D. Seiss, and S. Wong Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study J Immunother 29 2006 575 585
243. E.J. Wherry T cell exhaustion Nat Immunol 12 2011 492 499
244. S. Wilgenhof, and B. Neyns Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient Ann Oncol 22 2011 991 993
245. J.D. Wolchok, F.S. Hodi, J.S. Weber, J.P. Allison, W.J. Urba, and C. Robert Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma Ann N Y Acad Sci 1291 2013 1 13
246. J.D. Wolchok, A. Hoos, S. O'Day, J.S. Weber, O. Hamid, and C. Lebbé Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
247. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, and A.M. Lesokhin Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
248. J.D. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky, and L. Thomas Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 2010 155 164
249. J.D. Wolchok, J.S. Weber, O. Hamid, C. Lebbé, M. Maio, and D. Schadendorf Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials Cancer Immun 10 2010 1 6
250. S.-R. Woo, M.E. Turnis, M.V. Goldberg, J. Bankoti, M. Selby, and C.J. Nirschl Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape Cancer Res 72 2012 917 927
251. N. Yamazaki, H. Tahara, H. Uhara, Y. Moroi, and Y. Kiyohara Phase 2 study of nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in patients with advanced melanoma Eur J Cancer 49 Suppl. 2 2013 (Abstract 3738)
252. J.C. Yang, K.E. Beck, J.A. Blansfield, K.Q. Tran, I. Lowy, and S.A. Rosenberg Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010) J Clin Oncol 23 Suppl. 16 2005 (Abstract 2501)
253. L. Zimmer, T.K. Eigentler, J.-M. Vaubel, P. Mohr, Z. Jradi, and F. Kiecker Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups J Clin Oncol 32 Suppl. 15 2014 (Abstract 9031)